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Summary
Background: Microbial translocation from the gut lumen has been involved in the
pathogenesis of liver damage in hepatitis C virus (HCV) infection.
Aim: To investigate the impact of direct‐acting antiviral treatment on microbial
translocation and T‐cell activation, in patients with hepatitis C-related liver disease.
Methods: We enrolled two groups of HCV‐infected patients undergoing direct‐act-
ing antiviral treatment: patients with fibrosis ≥F3 according to Metavir (Group ≥F3);
patients with hepatitis C recurrence after liver transplantation and Metavir ≥F2
(Group Liver Transplantation + ≥F2). All patients were treated with direct‐acting
antivirals based on ongoing guidelines. Surrogate biomarkers of microbial transloca-
tion (plasma concentrations of soluble‐CD14, lipopolysaccharide‐binding protein and
intestinal fatty acid‐binding protein) were evaluated at baseline, at first month, at
the end of treatment and 3 months later. T‐cell activation was measured by expres-
sion of CD38+ HLA‐DR at the same time points, only in Group ≥F3.
Results: There were 32 patients in Group ≥F3 and 13 in Group LT + ≥F2. At base-
line, levels of soluble‐CD14 and lipopolysaccharide‐binding protein were significantly
higher in both groups vs healthy controls. Baseline soluble‐CD14 correlated with
glutamic‐oxalacetic transaminase (r = 0.384, P = 0.009) and glutamic‐pyruvic
transaminase (r = 0.293, P = 0.05). A significant decrease in plasma levels of surro-
gate microbial translocation biomarkers was observed during and after treatment in
the two groups although values were not normalised. In Group ≥F3, CD38+
HLADR+ T‐cell expression was significantly decreased by direct‐acting antiviral
treatment. Relapsers (9%) showed higher soluble‐CD14 levels at baseline.
Conclusion: Surrogate microbial translocation markers and T cell activation are
increased in HCV‐infected patients with liver fibrosis and decrease during direct‐act-
ing antiviral treatment.
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publication after full peer-review.
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1 | INTRODUCTION
Hepatitis C virus (HCV) infection is, at present, one of the most fre-
quent causes of cirrhosis in the western world, representing both a
social and substantial health burden.1
Until recently, the standard of care for treatment of HCV infec-
tion was the combination of pegylated interferon alpha and ribavirin,
which obtained virus clearance in a substantial fraction of patients,
but at a high cost in terms of side effects. The advent of the new
direct‐acting antivirals, by targeting the hepatitis C viral proteins
including NS3/4A, NS5A, and NS5B, changed dramatically the treat-
ment of HCV infection reaching a high rate of HCV eradication with
a low frequency of side effects.
Pro‐inflammatory status and pro‐fibrotic cytokines play an impor-
tant role in the pathogenesis of liver damage during HCV infection,
although the mechanisms involved are not completely clarified.2 Sev-
eral authors have reported that chronic inflammation and liver fibro-
sis in chronic HCV infection, are associated with microbial
translocation (MT), from the gut lumen to the systemic circulation.3-5
Indeed, lipopolysaccharide (LPS), which is a component of the outer
layer of Gram‐negative bacteria, is able to stimulate liver resident
Kupffer and hepatic stellate cells, thereby contributing to the devel-
opment of liver fibrosis.6 Several plasma proteins have been vali-
dated as biomarkers of microbial translocation. Among these,
lipopolysaccharide binding protein (LBP) and soluble CD14 (sCD14),
have been used to measure the degree of microbial translocation in
the peripheral blood.7-10 Intestinal fatty acid‐binding protein
(I‐FABP), reflecting enterocyte damage, is an additional biomarker
strictly related to microbial translocation.11,12 Microbial translocation
occurs as a consequence of disruption of the intestinal barrier integ-
rity. This condition is associated with a range of diseases such as
intestinal ischemia, inflammatory bowel disease, graft‐versus‐host
disease, and chronic viral infections including human immunodefi-
ciency virus (HIV) and hepatitis C virus.13,14 Microbial translocation
products are considered a driving force of systemic immune activa-
tion in which increase of CD38+ and HLADR+ expression is one of
the main feature.14
Few data are available about the role of microbial translocation
in patients with chronic hepatitis or cirrhosis related to HCV infec-
tion, and during and after HCV clearance. No data are available
about the liver transplanted patients with recurrence of HCV infec-
tion, who represent a particular population under immunosuppres-
sive treatment.
Changes in microbial translocation markers in subjects with HCV
infection treated with pegylated interferon and ribavirin have been
reported in two studies.15,16 Biomarkers of microbial translocation were
found to be associated with the treatment outcome; however, in both
studies, the results could have been partly influenced by the presence
of pegylated interferon alpha in the treatment regimen, which may
interfere with plasma levels of sCD14 by activating monocytes.
We therefore, conducted an observational study aiming at evalu-
ating the modifications of microbial translocation and of T cells
activation marker, in HCV-infected patients treated with direct‐act-
ing antiviral regimens.
2 | MATERIALS AND METHODS
Two groups of patients with chronic HCV infection, undergoing
direct‐acting antiviral therapy, were included in the study. The first
group included patients with HCV infection and advanced fibrosis
(F3‐F4 according to Metavir) (Group ≥F3). The second group
included patients with HCV recurrence after liver transplantation
(LT) and fibrosis ≥ F2 according to Metavir (Group LT + ≥F2). Exclu-
sion criteria in both groups were HIV co‐infection, inflammatory
bowel disease or other chronic intestinal diseases, alcohol abuse in
the last 3 months and other concomitant causes of liver disease in
addition to HCV infection.
A group of 11 healthy subjects were enrolled as controls for
basal microbial translocation surrogate biomarkers.
The following antiviral treatments were administered: inhibitor of
non‐structural protein 5B (NS5B) sofosbuvir together with ribavirin
for 24 weeks; sofosbuvir + inhibitor of NS4 (simeprivir) for
12 weeks in association with ribavirin (when indicated and in
absence of contraindications); sofosbuvir + inhibitor of NS5A (ledi-
pasvir or daclatasvir) for 12 or 24 weeks with or without ribavirin.
The choice of treatment for each patient was based on the current
guidelines according to the genotype, the characteristics of patients
and the availability of drugs in our country/region at that moment.
Chronic HCV infection was defined as persistence of HCV RNA
in serum 6 months after infection.17 Sustained virological response
for 12 weeks was defined as undetectable HCV RNA in serum at
12 weeks after completing therapy. Patients were evaluated at base-
line (before starting the antiviral therapy) (T = 0), first month after
initiation of treatment (T1), at the end of treatment (T2) and
3 months after the end of treatment (T3).
At each time‐point clinical and biochemical data (albumin,
International Normalised Ratio, cholinesterase, creatinine, urea,
Glutamic‐Oxalacetic Transaminases, Glutamic‐Pyruvic Transaminases,
γ‐glutamyl transpeptidase, Alkaline Phosphatase, bilirubin, complete
blood count, HCV‐RNA PCR, and genotype, Model of End stage
Liver Disease score) were recorded; microbial translocation markers,
such as sCD14, LBP and I‐FABP, were measured at the same time‐
points. The immunophenotypic study on T‐cells was performed in
Group ≥F3 but not in Group LT + ≥F2, where the chronic adminis-
tration of immunosuppressive drugs, by reducing T cell activation
and T‐helper‐cell dependent B‐cell proliferation could represent a
confounding factor.
Non‐invasive assessment of liver fibrosis was performed at T0
and T3 through Fibroscan® (Echosens, Paris). At least 10 valid mea-
surements, a 60% success rate, an interquartile range of less than
30% of the median elasticity, were required for eligibility.18
The study was approved by the Ethical Committee of La
Sapienza University Hospital, Rome (2454/15). All subjects signed a
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written informed consent before enrolment in the study. Data and
plasma samples were collected respecting donor's confidentiality and
privacy.
2.1 | Microbial translocation and enterocytes
damage biomarkers analysis
Peripheral blood was drawn from each patient fasting in the morning
in EDTA vials and processed within 24 hours. Plasma samples from
11 healthy individuals, were used as controls. Aliquots of plasma
samples were stored at −80° until required for analysis.
Soluble CD14 (sCD14, R&D Systems, Minneapolis, MN, USA),
Lipopolysaccharide Binding Protein (LBP) (LBP Human, ELISA Hycult
biotech, Uden The Netherlands) and Intestinal fatty acid binding pro-
tein (I‐FABP, Hycult Biotech, Uden,The Netherlands), were measured
in plasma according to the manufacturer's instructions. For each bio-
marker, the optimal dilutions were determined: 1:500 for sCD14;
1:1000 for LBP and 1:2 for IFABP.
2.2 | Flow cytometry analysis
Multi‐color flow cytometry analysis was performed on whole blood.
Fluorescence intensities were measured with Gallios cytometer and
analysed using Kaluza Analysis software version 1.3 (Beckman Coul-
ter, Brea, CA, USA) using cut‐offs based on isotype antibody stain-
ing. T‐cell subpopulations were determined using the following
fluorochrome‐conjugated antibodies: PerCP‐Cy5.5 anti‐CD3, PE‐Cy7
anti‐CD4, FITC anti‐CD8, in combination with Brilliant Violet 421
anti‐CD38, V500 anti‐HLA‐DR (all purchased from BD Biosciences,
San Diego, CA, USA).
2.3 | Statistical analysis
Statistical analyses and graphical presentation were done using SPSS
software, version 24 (IBM, Somers, NY, USA). Results are given as
the median, interquartile range (IQR) and percentage. Differences
between groups were evaluated using the χ2 test for categorical
variables and by Kruskal‐Wallis and Mann‐Whitney U test for quanti-
tative variables. Spearman's correlation coefficient was used to eval-
uate correlations between quantitative variables. Differences were
considered statistically significant when P < 0.05.
3 | RESULTS
3.1 | Study population
Forty‐five subjects with chronic HCV hepatitis were included in the
study: 32 patients in Group ≥F3 and 13 patients in Group LT +
≥F2. All patients in the latter group were receiving immunosup-
pressive therapy to prevent graft rejection. The baseline character-
istics of the patients are shown in Table 1. Eleven healthy subjects
(73% males, median age 48 ± 5.4 years) were utilised as control
group.
Severe fibrosis was almost universal in Group ≥F3 (F4 91%) but
less frequent in the transplanted patients at the time of treatment
(F4 38% P < 0.05). Due to the characteristics of patients (including
genotype) and drugs available at the time of treatment, direct‐acting
antiviral regimens were different in the two groups: most of the
patients in Group ≥F3 were treated with sofosbuvir + NS5A inhibi-
tor (ledipasvir or daclatasvir) (53%), followed by those treated with
sofosbuvir + simeprevir (38%) and with sofosbuvir alone (9%). On
the other hand, patients of Group LT + ≥F2 were treated mostly
with sofosbuvir alone (62%), followed by sofosbuvir + simeprevir
(38%). Ribavirin was used in all transplanted patients and in 50% of
Group ≥F3.
3.2 | Virological outcome
A sustained virological response at 12 weeks was obtained in thirty
patients (94%) in Group ≥F3 and in eleven patients (85%) in Group
LT + ≥F2. Modifications in liver function tests, viral load and
TABLE 1 Baseline characteristics of the two group of patients at
enrolment
Group ≥ F3 Group LT + ≥F2 P value
Patients n 32 13
Age (y) 59 (52.0‐70.2) 65 (55.0‐66.5) 0.437
Male Gender n (%) 24 (75) 10 (77) 0.600
HCV genotype n (%)
1 22 (69) 8 (62) 0.400
2 2 (6) 1 (8)
3 7 (22) 2 (15)
4 1 (3) 2 (15)
SVR12 n (%) 30 (94%) 11 (85%) 0.300
Metavir, n (%)
F2 0 6 (46) <0.050
F3 3 (9) 2 (15)
F4 29 (91) 5 (38)
MELD score 9.0 (7‐11.0) 9.0 (7.0‐10.5) 0.400
Gastro-oesophageal varices, n (%)
None 19 (59) 12 (92) 0.070
F1 7 (22) 0
≥F2 6 (19) 1 (8)
Ascites, n (%) 0 0 —
Time from LT (mo) — 105 (16‐225) —
Immunosuppressive treatment, n (%)
Tacrolimus — 8 (62) —
Everolimus — 3 (24)
Sirolimus — 1 (7)
Cyclosporine — 1 (7)
Values are expressed as medians (IQR) or percentages.
HCV: hepatitis C virus; LT: liver transplantation; MELD: model for end
stage liver disease; SVR: sustained virological response.
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ultrasonography parameters before, during and after treatment are
shown in Table 2. An amelioration in transaminases, serum albumin
levels, and liver stiffness was observed in both groups during and
after treatment.
3.3 | Basal LBP, sCD14 and I‐FABP in HCV patients
and healthy controls
Baseline levels of markers of microbial translocation and enterocyte
damage are reported in Figure 1. In both groups, plasma levels of
LBP, sCD14, and I‐FABP were increased when compared to healthy
subjects. Plasma values measured in this latter group were consistent
with those reported for adult healthy population in the individual
package inserts of the relevant ELISA assays.
Specifically, median sCD14 values at baseline in HCV patients of
were significantly higher in comparison with healthy controls
(1176.0 ng/mL, IQR: 1048.0‐1358.0; P < 0.0001) with no differences
between group ≥F3 and group LT + ≥F2 (1928.5 ng/mL, IQR:
1441.8‐2321.5 vs 2117.5 ng/mL, IQR: 1814.5‐2161.5 P = 0.430).
Baseline LBP level, on the other hand, were higher in Group LT +
≥F2, followed by Group ≥F3 (22.5 mg/mL IQR: 18.1‐24.9 vs
14.1 mg/mL, IQR: 11.8‐17.0, respectively; P = 0.001) and controls
(8.9 mg/mL, IQR: 7.8‐10.4; P < 0.0001). Concerning I‐FABP, baseline
levels were significantly higher in Group LT + ≥F2 in comparison
with controls (728.0 pg/mL, IQR: 338.0‐1008.0, vs 277.2 pg/mL, IQR:
173.0‐374.0, P = 0.008). sCD14 levels in both groups significantly
correlated with I‐FABP (r = 0.342; P = 0.01) and LBP (r = 0.430;
P = 0.001) (Figure S1).
To better understand the clinical significance of our findings, we
analysed potential correlations between baseline sCD14 levels and
markers of hepatic necrosis, fibrosis, and liver protein synthesis. We
found that sCD14 plasma levels were associated with the increase
of glutamic‐oxalacetic transaminase (r = 0.384, P = 0.009) and glu-
tamic‐pyruvic transaminases (r = 0.293, P = 0.05). No association
TABLE 2 Longitudinal changes in hepatic markers during direct‐acting antivirals treatment in two group of patients
Group 1 TIME 0 (Baseline) TIME 1 (1st month) TIME 2 (End of treatment)
TIME 3 (3rd month after
end of treatment)
ALP (U/L) 110 (92.0‐149.5) 91.0 (76.8‐126.5)** 85.0 (78.5‐100.5)* 91.5 (77.3‐122.8)
GOT (U/L) 62.5 (40.0‐97.8) 30.0 (23.0‐37.0)*** 25.0 (21.5‐32.5)*** 27.0 (22.0‐32.0)***
GPT (U/L) 62.0 (40.0‐117.0) 28.0 (16.0‐40.0)*** 24.0 (17.5‐35.0)*** 29.0 (20.0‐37.0)***
GGT (U/L) 72.0 (52.3‐115.8) 44.0 (20.0‐72.0)* 32.0 (20.0‐59.0)** 32.0 (21.0‐87.0)
MELD score 9.0 (7.0‐11.0) 9.5 (8.0‐12.0)** 9.0 (7.3‐12.0) 8.0 (7.0‐11.0)
HCV RNA (detectable n, %) 32 (100%) 5 (15.7%) 0 (0%) 2 (6.3%)
Stifness (kPa) 23.9 (16.3‐28.7) ND ND 14.7 (8.7‐19.0)***
Albumin (gr/dL) 3.75 (3.40‐4.10) 3.95 (3.63‐4.28)* 4.00 (3.70‐4.40) 4.00 (3.80‐4.20)**
INR 1.14 (10.8‐1.38) 1.20 (1.10‐1.30) 1.18 (1.07‐1.36) 1.17 (1.09‐1.38)
Platelets (x103) 105 (71.2‐128) 113 (70‐153) 103 (63‐131) 95.5 (59.2‐142)
Portal vein diameter (mm) 12.8 (11.8‐13.9) ND ND 12.9 (11.6‐14.1)
Spleen longitudinal diameter (cm) 14.6 (12.7‐16.9) ND ND 13.8 (12.6‐16.6)
Group 2
ALP (U/L) 106.0 (77.5‐116.5) 87.0 (75.0‐113.5)* 92.0 (72.0‐107.0) 73.5 (62.0‐91.0)**
GOT (U/L) 51.0 (30.0‐81.0) 19.0 (16.5‐30.5)** 21.0 (15.0‐22.5)** 16.5 (16.0‐28.0)*
GPT (U/L) 72.0 (39.5‐100.0) 19.0 (18.0‐28.5)*** 16.0 (13.0‐28.0)** 17.0 (14.0‐33.5)*
GGT (U/L) 72.0 (40.5‐185.5) 44.0 (18.3‐83.8)** 20.0 (12.5‐35.0)* 25.5 (16.0‐43.0)*
MELD score 9.0 (7.0‐10.5) 9.0 (7.5‐12.0) 10.0 (7.0 ‐13.0) 9.5 (7.25‐10.8)
HCV RNA (detectable n, %) 13 (100%) 6 (46.2%) 1 (7.7%) 2 (15.4%)
Stifness (kPa) 11.9 (8.1‐15.3) ND ND 6.9 (6.1‐11.6)*
Albumin (gr/dL) 4.30 (4.00‐4.40) 4.30 (4.20‐4.50) 4.30 (4.05‐4.40) 4.50 (4.25‐4.65)*
INR 1.07 (1.05‐1.15) 1.10 (1.03‐1.22) 1.12 (10.5‐1.23) 1.09 (1.05‐1.10)
Platelets (x103) 142 (110‐175) 165 (131‐231)* 145 (128‐222)* 153 (118‐224)
Portal vein diameter (mm) 12.6 (10.0‐16.0) ND ND 13.2 (12.1‐14.1)
Spleen longitudinal diameter (cm) 13.7 (12.8‐15.9) ND ND 14.1 (12.0‐16.0)
Data are expressed as median (IQR).
ALP: alkaline phosphatase; GGT: γ‐glutamyl transpeptidase; GOT: glutamic‐oxalacetic transaminase; GPT: glutamic‐pyruvic transaminase; HCV: hepatitis
C virus; INR: international normalised ratio; MELD: model for end‐stage liver disease; ND: not done.
Asterisks indicate statistical differences with respect to baseline values *P < 0.05; **P < 0.001; ***P < 0.0001.
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was found between sCD14 plasma levels and albumin or INR plasma
levels and indirect signs of portal hypertension (spleen diameter, the
presence of oesophageal varices). No correlation was found between
sCD14, LBP or I‐FABP levels and liver stiffness (kPa) (P = 0.876;
P = 0.091; P = 0.813 respectively) nor with baseline viral load. A
weak correlation was found between I‐FABP and MELD score
(r = 0.303; P = 0.045, Figure 2).
3.4 | Changes of LBP, I‐FABP, and sCD14 during
direct‐acting antiviral treatment
In group ≥F3, following the sharp decrease of viral load during the
first month of treatment, plasma levels of sCD14 and LBP showed a
rapid and significant decline. Three months after the end of the
treatment sCD14 and LPB plasma levels remained significantly lower
with respect to baseline (P = 0.016 and P = 0.04, respectively).
I‐FABP plasma levels showed a minor non‐significant decline during
direct‐acting antiviral treatment (Figure 3).
Patients in group LT + ≥F2 experienced a less pronounced
decrease in surrogate markers of microbial translocation when com-
pared with patients in group ≥F3. sCD14, I‐FABP, and LBP plasma
level did not show significant variations with respect to baseline values
during the first month of direct‐acting antiviral treatment. Only LBP
levels showed a significant decrease at T3 (P = 0.016) with respect to
baseline levels. However, at T3 all markers of microbial translocation
in Group LT + ≥F2 patients were still more elevated than in controls
(Figure 3).
No significant difference was observed in microbial translocation
biomarkers changes with respect to different types of direct‐acting
antiviral treatments.
3.5 | Changes in T‐cells activation markers
expression in Group 1 during direct‐acting antiviral
treatments
With the aim of exploring the impact of direct‐acting antivirals on
T‐cell activation, we measured the variations in the CD38+HLADR+
expression on CD4+ and CD8+ T‐cells. As expected, the percentage
of total CD4+ (median: 63.5%, IQR: 58.4‐68.6) and CD8+ cells (me-
dian: 30.7%, IQR: 24.5‐34.1) remained stable during the direct‐acting
antiviral treatment, but in both lymphocyte populations a significant
decrease was seen in the subset of cells expressing the marker of
activation CD38+HLADR+, paralleled by the decrease of sCD14. At
T3 the percentage of CD4+ and CD8+ expressing CD38+HLADR+
receptors were reduced by 40.8% (P = 0.001) and 64%, P = 0.004)
respectively, respect to baseline (Figure 4).
3.6 | Factors associated with HCV relapse
Only four patients (two in each group), experienced HCV relapse
after treatment. Age, gender, viral genotype, and viral load, type of
treatment, baseline stiffness (kPa), baseline LBP and I‐FABP levels
were similar in patients reaching SVR 12 and in those with relapse.
On the other hand, we observed that in both groups, the sCD14
levels at baseline were significantly higher in the relapsers with
respect to patients with SVR12 (2582.5 ng/mL vs 1777.5 ng/mL,
P = 0.019). Nevertheless, the trend in sCD14 decrease during treat-
ment was similar in patients with and without SVR.
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4 | DISCUSSION
HCV infection represents one of the most important causes of
liver disease in the western world. In recent years, direct‐acting
antiviral therapy has produced a dramatic change in the outcome
of HCV infected patients and in the epidemiology of liver
diseases.19
Microbial translocation and chronic inflammation have been
found to be associated with the progression of liver damage, but
few studies have explored the modifications induced by direct‐acting
antiviral treatments on microbial translocation and T‐cell activation
in HCV patients.
The main findings of our study were the following: (a) plasma
levels of sCD14 and LBP, surrogate markers of microbial
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translocation, are significantly higher in untreated HCV infected
patients than in healthy subjects; (b) the elevated levels of sCD14
correlate with transaminases levels; (c) Direct‐acting antiviral treat-
ments induced a significant decrease in microbial translocation surro-
gate markers and a significant decrease of CD38+HLADR+
expression on T lymphocytes in patients in Group ≥F3. Furthermore,
viral relapse after treatment was associated with higher plasma levels
of sCD14 at baseline in our population.
To our knowledge, this is one of the first studies in which
changes in plasma levels of microbial translocation markers during
direct‐acting antiviral treatments are analysed and no study to date
evaluated this aspect in a population with the recurrence of HCV
after liver transplantation.
High levels of surrogate microbial translocation markers in HCV
patients confirm the observation by other authors3,16,20 who also
suggested that microbial translocation may contribute to persistent
inflammation and development of fibrosis in chronic HCV infec-
tion.16 Even if the mechanism underlying the link between HCV
infection and microbial translocation was beyond the purpose of our
study, a possible explanation could be related to gut epithelial dam-
age, as was observed in a study21 conducted in HIV/HCV coinfected
patients, in whom HIV is known to colonise enterocytes. However,
I‐FABP, which is a marker of enterocyte damage,12 was not
increased in our series, suggesting that the pathogenetic role of gut
epithelial damage is unlikely in our patients. Portal hypertension,
derived from liver fibrosis and portosystemic shunting, has also been
claimed to cause an alteration of intestinal permeability mainly in cir-
rhotic patients22; this could partially contribute to explain the
increase in microbial translocation surrogate markers in our series of
compensated advanced liver disease (Group ≥F3) with presence of
oesophageal varices in 41% of patients.
Immunological impairment can also lead to a less efficient
intestinal barrier and increased microbial translocation as is the case
in other conditions of immunodeficiency.23-25 This may be sup-
ported by the observation that liver transplanted patients (group LT
+ ≥F2), receiving chronic immunosuppressive therapy, showed
higher levels of microbial translocation respect to group ≥F3, in the
absence of portal hypertension in the majority of them. Indeed, in
group LT + ≥F2, sCD14, as well as other surrogate biomarkers of
microbial translocation, tended to be higher than in group ≥F3. This
is consistent with previous reports that have shown a persistent sta-
tus of immune activation, likely due to subclinical infections associ-
ated with lifelong immunosuppressive therapy, in liver transplant
patients.26,27 Increased levels of LBP have also been reported during
acute and chronic rejections,25 our patients, however, had no signs
of rejection.
In both groups, the levels of sCD14 were elevated when com-
pared to healthy subjects and correlated with transaminases levels.
Similar findings have been described in a cohort of HCV patients by
Sandler et al16 who also found a significant correlation between
microbial translocation and the degree of liver fibrosis. Although
these patients were rather similar to those in our cohort, we failed
to find an association between microbial translocation surrogate
markers and Metavir. Indeed, sCD14 and I‐FABP levels were similar
in patients with different degree of fibrosis. The different methods
utilised for the assessment of liver fibrosis (liver biopsy vs Fibroscan)
could have also influenced the results.
Moreover, despite portal hypertension is known to cause an
alteration of intestinal permeability, we failed to find this association
in our study. This was probably due to the mild degree of portal
hypertension in our series. In fact, as shown in Table 1, none of our
patients had experienced ascites and only 7 patients (15%) had
varices ≥ F2. In the contest of compensated liver disease, it is likely
that other mechanisms, such as hepatic inflammation, intestinal dam-
age and alteration in immune system, could have been more relevant
as a cause of microbial translocation.
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To support the association between monocyte activation and the
release of bacterial translocation products in our series we found
that sCD14 levels were directly correlated with LBP.
Direct‐acting antiviral treatment induced HCV clearance in the
large majority of patients (91%) and caused improvement of liver
function, as indicated by the amelioration of all liver function tests.
Viral eradication was paralleled by a significant decline of sCD14
and LBP in group ≥F3 and a significant reduction of LBP in group
LT + ≥F2 patients. The decrease of sCD14 and LBP levels, although
not reaching normal values, persisted 3 months after the end of
antiviral treatment. Previous studies on the impact of direct‐acting
antivirals on systemic immune activation in HCV patients have
reported controversial results; while some studies highlighted a
reduction of the markers of immune activation during direct‐acting
antiviral treatment,28 others did not find similar changes.20
The rapid decline of microbial translocation surrogate markers
after direct‐acting antiviral treatment suggests that viral clearance
may affect microbial translocation. This makes unlikely a relevant
role of portal hypertension, mainly in group ≥F3, as the amelioration
of portal hypertension, when reversible, is known to take longer than
3 months after eradication.29
The evidence that direct‐acting antiviral therapy, through HCV
clearance, can modify the immune system is provided by studies
about HCV‐cryoglobulinemia vasculitis in which direct‐acting
antivirals effectively normalises many of the abnormalities in periph-
eral B‐ and T‐lymphocytes homeostasis.30 Specific restoration of pro-
liferative CD8+ T‐cell responses was observed, when lymphocytes
were stimulated by HCV antigens, following HCV elimination by an
interferon‐free direct‐acting antiviral regimens31 and it has been
reported that successful interferon‐free therapy prevented inter-
feron‐mediated intrahepatic immune activation and resulted in nor-
malisation of Natural Killer cell functions.32,33
T regulatory cells play an important role in HCV infection, both
in the maintenance of chronicity by inhibiting anti‐HCV immune
responses and in attenuating the intrahepatic tissue‐damaging
response to infection.34 Literature data exist also indicating that in
chronic HCV infection colonic T regulatory cells are higher than in
controls35 and this finding may lead to alteration in the gut barrier
and increased microbial translocation, potentially reversible after
therapy.
In our study, after direct‐acting antiviral treatment, we found a
significant decline in markers of T‐cell activation. A previous study
also reported a decline of T‐cells CD38+HLADR+ expression in
chronic HCV patients, after interferon‐free treatment.36
The immunophenotypic analysis was performed only in Group
≥F3, since it is known that the chronic immunosuppressive therapy,
as administered in patients in Group LT + ≥F2, could impact on the
CD38 expression on T‐cells. Indeed, it has been reported that CD38
expression on T‐cells is under‐expressed after anti‐rejection therapy,
and its determination has been proposed as assay to be used rou-
tinely to quantify the level of immunosuppression in clinical prac-
tice.37
Overall, our results suggest that direct‐acting antiviral treatment
is associated to a reduction in inflammation and generalised immune
activation. It can be speculated that, this will lead to a reduction in
cirrhosis‐related complications, including arterial vasodilatation,
hyperdynamic circulation and bacterial infections.38 Further studies,
with longer follow up are needed to confirm this hypothesis.
As expected, the relapse rate was very low in our patient popula-
tion, occurring only in 4 subjects (2 in Group ≥F3 and 2 in Group LT
+ ≥F2). Interestingly, these patients, independently from groups,
showed baseline sCD14 levels significantly higher when compared
to patients who achieved an SVR. The pattern of decrease of micro-
bial translocation markers during treatment was similar to other
patients. A possible explanation derives from the observation that all
these patients initially responded to the therapy and cleared HCV,
with the relapse occurring later on, after the end of treatment.
Although the number of cases does not allow any further specula-
tions, it is noteworthy that in a previous study the high baseline
sCD14 level in patients receiving antiviral treatment (interferon or
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PEG‐interferon with or without ribavirin) was significantly associated
with treatment failure.16
Our study, to our knowledge, is one of the first studies where
changes of microbial translocation markers during direct‐acting
antiviral treatment were evaluated in a population of liver trans-
planted patients with HCV infection recurrence. The study has, how-
ever, some limitations: first, the limited number of patients; second,
we did not measure directly LPS plasma levels. However, measuring
LPS concentration is a technically complex process that can be fur-
ther complicated by its rapid clearance and by the presence of inhi-
bitory plasma proteins.39-41 In this view, LPS‐binding protein (LBP), a
protein with a relatively long half‐life synthesised by the liver in
response to bacteraemia,42,43 can be considered a reasonable surro-
gate biomarker for assessing LPS‐induced inflammation in humans.
At the same time, as for many other acute phase proteins, the liver
is directly responsible for LBP synthesis,44 and the LBP upregulation
may be compromised in case of an impaired capacity of the liver,45
making the interpretation of results sometimes difficult. Moreover, it
is important to underline that this study refers to first generation
direct‐acting antivirals.
In conclusion, our findings suggest that direct‐acting antiviral
therapy can significantly reduce plasma levels of microbial transloca-
tion biomarkers and proportion of activated T‐cells in HCV patients
with advanced fibrosis. These effects persist at 3 months after the
end of therapy. Further studies, conducted in larger cohorts of
patients, with longer follow up, will allow to understand the possible
clinical consequences of the reduction/normalisation of systemic
inflammation.
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